180 related articles for article (PubMed ID: 21603990)
1. Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
Selzer E; Liederer S; Lemaire C; Kren G; Radonjic D; Kornek G; Knocke T; Pötter R; Bachtiary B
Strahlenther Onkol; 2011 Jun; 187(6):373-7. PubMed ID: 21603990
[TBL] [Abstract][Full Text] [Related]
2. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
Chan A; Teoh D; Sanghera P; Hartley A
Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
[No Abstract] [Full Text] [Related]
4. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
Valeriani M; Muni R; Osti MF; De Sanctis V; Minniti G; Ardito F; Maurizi Enrici R
Radiol Med; 2012 Feb; 117(1):125-32. PubMed ID: 21892718
[TBL] [Abstract][Full Text] [Related]
5. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
[TBL] [Abstract][Full Text] [Related]
6. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
[TBL] [Abstract][Full Text] [Related]
10. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
11. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.
Studer G; Brown M; Salgueiro EB; Schmückle H; Romancuk N; Winkler G; Lee SJ; Sträuli A; Kissling B; Dummer R; Glanzmann C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):110-7. PubMed ID: 20732757
[TBL] [Abstract][Full Text] [Related]
12. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
15. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
17. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
[TBL] [Abstract][Full Text] [Related]
18. Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.
Kurokawa M; Watanabe Nemoto M; Harada R; Kobayashi H; Horikoshi T; Kanazawa A; Togasaki G; Abe Y; Chazono H; Hanazawa T; Okamoto Y; Uno T
J Radiat Res; 2015 Sep; 56(5):849-55. PubMed ID: 26160181
[TBL] [Abstract][Full Text] [Related]
19. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab.
Bölke E; Gerber PA; Lammering G; Peiper M; Müller-Homey A; Pape H; Giro C; Matuschek C; Bruch-Gerharz D; Hoffmann TK; Gripp S; Homey B; Budach W
Strahlenther Onkol; 2008 Feb; 184(2):105-10. PubMed ID: 18259703
[TBL] [Abstract][Full Text] [Related]
20. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]